More than Half of Health Care Industry Execs Expect 340B Reporting Requirements Within Five Years

A message from 340B Report Publisher and CEO Ted Slafsky: We are pleased to have a sponsored content article today from Michael Gonzalez, President and Lead Consultant, FQHC340B, a valued 340B Report sponsor. I encourage you to read it. We will

Read More »

MedPAC Report Endnote Sheds Light on Hospital Losses Due to CMS 340B Drug Payment Cuts


Happy Juneteenth from Publisher and CEO Ted Slafsky: Our sponsors are 340B’s industry leaders and we are proud to showcase their innovative solutions and guidance to help you implement and comply with this complex program. Benefits

Read More »

The CMS 340B Drug Cost Survey Is a Wrap. So, What Happens Now?


Editor’s note: Our next regularly scheduled edition will be on Thursday, May 28 due to the Memorial Day holiday weekend. We’ll publish an extra edition for any breaking news.

A note from 340B Report Publisher and

Read More »

Two More National Hospitals Groups Urge CMS to Stop 340B Drug Cost Survey


A note from 340B Report CEO and Publisher Ted Slafsky: Today’s issue includes the fourth in our ongoing series of articles by 340B Report sponsors that draw on their deep expertise. Click on the button below

Read More »

Largest Hospital Group to CMS: 340B Drug Survey Is Burdensome, Ill-Timed, Illegal


A note from 340B Report CEO and Publisher Ted Slafsky: Today’s issue includes the third in our ongoing series of articles by 340B Report sponsors that draw on their deep expertise. Click on the button below

Read More »

All Indications Are CMS Plans to Launch its 340B Drug Acquisition Survey on Monday

Editor’s note, March 20, 2020: When we published Tweets of Note yesterday, we were unaware of health care economist’s Rena Conti’s March 14 reply to a critic’s tweet the same day. We have added it to this web version of

Read More »

Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing

Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing

Do 340B drug discounts induce hospitals to furnish more-expensive drugs to treat cancer than they otherwise would, raising patients’ coinsurance obligations and the cost of

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live